Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Eisai Inc.
Robert J Motzer; Camillo Porta; Masatoshi Eto; Thomas Powles; Viktor Grünwald; Thomas E Hutson; Boris Alekseev; Sun Young Rha; Jaime Merchan; Jeffrey C Goh; Aly-Khan A Lalani; Ugo De Giorgi; Bohuslav Melichar; Sung-Hoo Hong; Howard Gurney; María José Méndez-Vidal; Evgeny Kopyltsov; Sergei Tjulandin; Teresa Alonso Gordoa; Vadim Kozlov; Anna Alyasova; Eric Winquist; Pablo Maroto; Miso Kim; Avivit Peer; Giuseppe Procopio; Toshio Takagi; Shirley Wong; Jens Bedke; Manuela Schmidinger; Karla Rodriguez-Lopez; Joseph Burgents; Cixin He; Chinyere E Okpara; Jodi McKenzie; Toni K Choueiri; CLEAR Trial Investigators